Alentis Therapeutics
Allschwil
About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $365.4M
- Funding stage: Late Stage Venture
- Last round: Series D (Nov 2024)
- Website: alentis.ch
- Phone: [email protected]
Industries & Categories
Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/alentis-therapeutics-49214 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.